Genomic Health Inc. (GHDX) COO G Bradley Cole Sells 8,290 Shares
Genomic Health Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 8,290 shares of the firm’s stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $30.59, for a total value of $253,591.10. Following the completion of the sale, the chief operating officer now directly owns 39,426 shares in the company, valued at $1,206,041.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
G Bradley Cole also recently made the following trade(s):
- On Thursday, August 11th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $28.87, for a total value of $144,350.00.
Genomic Health Inc. (NASDAQ:GHDX) opened at 28.91 on Thursday. The stock’s 50 day moving average is $28.21 and its 200 day moving average is $27.28. The stock’s market capitalization is $964.03 million. Genomic Health Inc. has a 12-month low of $20.05 and a 12-month high of $35.79.
Genomic Health (NASDAQ:GHDX) last issued its earnings results on Tuesday, August 2nd. The company reported ($0.18) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.18). The business had revenue of $81.97 million for the quarter, compared to the consensus estimate of $81.27 million. Genomic Health had a negative net margin of 8.84% and a negative return on equity of 21.02%. The company’s revenue for the quarter was up 16.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.29) EPS. Equities analysts predict that Genomic Health Inc. will post ($0.47) earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the company. Independent Portfolio Consultants Inc. increased its position in shares of Genomic Health by 54.5% in the second quarter. Independent Portfolio Consultants Inc. now owns 17,595 shares of the company’s stock worth $456,000 after buying an additional 6,210 shares in the last quarter. Royal Bank of Canada increased its position in Genomic Health by 6,543.0% in the first quarter. Royal Bank of Canada now owns 8,503 shares of the company’s stock worth $210,000 after buying an additional 8,375 shares in the last quarter. Renaissance Technologies LLC increased its position in Genomic Health by 54.0% in the first quarter. Renaissance Technologies LLC now owns 446,021 shares of the company’s stock worth $11,048,000 after buying an additional 156,421 shares in the last quarter. HBK Investments L P acquired a new position in Genomic Health during the first quarter worth about $886,000. Finally, Kimelman & Baird LLC increased its position in Genomic Health by 2.3% in the first quarter. Kimelman & Baird LLC now owns 21,940 shares of the company’s stock worth $543,000 after buying an additional 500 shares in the last quarter. Institutional investors and hedge funds own 88.92% of the company’s stock.
Several analysts recently issued reports on GHDX shares. Zacks Investment Research raised Genomic Health from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Tuesday, October 4th. Jefferies Group raised their target price on Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, August 17th. Canaccord Genuity reissued a “buy” rating and issued a $38.00 target price on shares of Genomic Health in a research note on Friday, August 5th. Leerink Swann reissued a “buy” rating on shares of Genomic Health in a research note on Tuesday, June 21st. Finally, Bank of America Corp. set a $28.00 target price on Genomic Health and gave the stock a “sell” rating in a research note on Wednesday, August 3rd. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $32.50.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.